[go: up one dir, main page]

WO2011049960A9 - Compositions et méthodes pour le traitement des troubles nasosinusiens - Google Patents

Compositions et méthodes pour le traitement des troubles nasosinusiens Download PDF

Info

Publication number
WO2011049960A9
WO2011049960A9 PCT/US2010/053217 US2010053217W WO2011049960A9 WO 2011049960 A9 WO2011049960 A9 WO 2011049960A9 US 2010053217 W US2010053217 W US 2010053217W WO 2011049960 A9 WO2011049960 A9 WO 2011049960A9
Authority
WO
WIPO (PCT)
Prior art keywords
sinonasal
disorders
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/053217
Other languages
English (en)
Other versions
WO2011049960A2 (fr
Inventor
Jay Lichter
Carl Lebel
Fabrice Piu
Jeffrey P. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otonomy Inc
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Otonomy Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otonomy Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Otonomy Inc
Publication of WO2011049960A2 publication Critical patent/WO2011049960A2/fr
Publication of WO2011049960A9 publication Critical patent/WO2011049960A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
PCT/US2010/053217 2009-10-21 2010-10-19 Compositions et méthodes pour le traitement des troubles nasosinusiens Ceased WO2011049960A2 (fr)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US25378209P 2009-10-21 2009-10-21
US61/253,782 2009-10-21
US25537909P 2009-10-27 2009-10-27
US61/255,379 2009-10-27
US25578309P 2009-10-28 2009-10-28
US25578009P 2009-10-28 2009-10-28
US61/255,783 2009-10-28
US61/255,780 2009-10-28
US29713810P 2010-01-21 2010-01-21
US29717010P 2010-01-21 2010-01-21
US61/297,138 2010-01-21
US61/297,170 2010-01-21
US36428710P 2010-07-14 2010-07-14
US61/364,287 2010-07-14
US36667710P 2010-07-21 2010-07-21
US61/366,677 2010-07-21

Publications (2)

Publication Number Publication Date
WO2011049960A2 WO2011049960A2 (fr) 2011-04-28
WO2011049960A9 true WO2011049960A9 (fr) 2011-08-18

Family

ID=43900967

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/053217 Ceased WO2011049960A2 (fr) 2009-10-21 2010-10-19 Compositions et méthodes pour le traitement des troubles nasosinusiens
PCT/US2010/053616 Ceased WO2011050206A2 (fr) 2009-10-21 2010-10-21 Compositions et procédés pour le traitement de troubles sino-nasaux

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2010/053616 Ceased WO2011050206A2 (fr) 2009-10-21 2010-10-21 Compositions et procédés pour le traitement de troubles sino-nasaux

Country Status (1)

Country Link
WO (2) WO2011049960A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
AU2012211514B2 (en) * 2006-10-24 2014-07-31 Aradigm Corporation Concentrated, inhalable ciprofloxacin formulation
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2013009761A1 (fr) 2011-07-13 2013-01-17 The Foundry, Llc Procédés et appareil pour administrer un agent thérapeutique à des cibles de la muqueuse nasopharyngée
SG11201407676VA (en) * 2012-05-21 2015-03-30 Agency Science Tech & Res A dry powder formulation
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
DE202013000748U1 (de) 2013-01-24 2013-02-19 Merz Pharma Gmbh & Co. Kgaa Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
DE102013001151A1 (de) 2013-01-24 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
EP2759290B1 (fr) 2013-01-24 2019-11-06 Merz Pharma GmbH & Co. KGaA Composition liquide pulverisable pour application nasale avec un delai local retentissant augmente
US20140371305A1 (en) * 2013-06-14 2014-12-18 Professional Compounding Centers Of America Mupirocin Antibiotic Composition
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
WO2015061025A1 (fr) 2013-10-22 2015-04-30 Aradigm Corporation Formulations liposomales à inhaler dont le tensioactif a été modifié apportant un profil de libération à la fois immédiate et prolongée
PT3142643T (pt) 2014-05-15 2019-10-28 Insmed Inc Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
EP3164115A4 (fr) 2014-07-03 2017-05-17 Otonomy, Inc. Stérilisation d'une composition de ciprofloxacine
CN104341405B (zh) * 2014-09-25 2016-09-14 武汉大学 一种具有抑制Aβ聚集活性的化合物的制备方法与用途
WO2017105356A1 (fr) 2015-12-18 2017-06-22 Ak-Kim Kimya Sanayi Ve Ticaret Anonim Sirketi Module de membrane à fibres creuses
CN105902543B (zh) * 2016-04-28 2019-02-12 华北制药股份有限公司 一种高纯度美洛西林钠制剂及其制备方法
US20180071281A1 (en) * 2016-08-19 2018-03-15 Gerbe Labs Inc. Treating chronic rhinosinusitis
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
KR20210024451A (ko) 2018-05-02 2021-03-05 인스메드 인코포레이티드 리포솜 약물 제형을 제조하는 방법
CN110141559A (zh) * 2019-06-18 2019-08-20 浦易（上海）生物技术有限公司 一种用于鼻粘膜的含药缓释微粒及其应用
US20210315973A1 (en) * 2020-04-08 2021-10-14 Nostrum Pharmaceuticals, Llc Compositions and methods using interferon for treating viral respiratory infections
US20220135653A1 (en) * 2020-11-05 2022-05-05 Bravado Pharmaceuticals, LLC Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections
CN113456580B (zh) * 2021-07-21 2024-03-22 沈阳化工大学 一种白藜芦醇原位凝胶制备及其表征方法
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164227B (it) * 1983-05-13 1987-04-08 Angeli Inst Spa Composizione farmaceutica atta alla somministrazione nasale di sali quaternari d'ammonio ed attivita' anticolinergica
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system

Also Published As

Publication number Publication date
WO2011050206A2 (fr) 2011-04-28
WO2011050206A3 (fr) 2011-09-22
WO2011049960A2 (fr) 2011-04-28

Similar Documents

Publication Publication Date Title
WO2011049960A9 (fr) Compositions et méthodes pour le traitement des troubles nasosinusiens
EP2552433A4 (fr) Compositions et procédés pour le traitement de troubles somatosensoriels
EP2293800A4 (fr) Compositions et procédés pour le traitement de troubles de l'oreille
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
IL215592A0 (en) Compositions and methods for the treatment of inflammation
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
EP2429584A4 (fr) Procédés et compositions de traitement
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
WO2011071995A9 (fr) Composés et procédés de traitement de troubles oculaires
SI2300614T1 (sl) Metode in sestavki za zdravljenje mitohondrijskih motenj
PL2437742T3 (pl) Nowe kompozycje do leczenia cmt i pokrewnych zaburzeń
IL214349A0 (en) Compositions and methods for the treatment of cancer
WO2012021287A9 (fr) Procédés pour le traitement et la prévention de maladies métaboliques
ZA201103572B (en) Compositions and methods for treatment of kidney disorders
WO2011112588A9 (fr) Compositions et méthodes pour le traitement de troubles inflammatoires
HU0900231D0 (en) Compositions for the treatment of allergic disorders
EP2461870A4 (fr) Compositions thérapeutiques et procédés associés
WO2010111374A9 (fr) Compositions et procédés pour soulager des affections cutanées
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0808730D0 (en) Compositions and methods for the prevention and treatment of schistosomiasis
AU2010904906A0 (en) Methods and compositions for the treatment and prevention of skin disorders
AU2010902219A0 (en) Compositions and methods for treating neurodegenerative disorders
GB0921929D0 (en) Compositions and methods for the treatment of influenza
HK1189155A (en) Treatment of mecp2-associated disorders
AU2009900341A0 (en) Method for the treatment of mental disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10825526

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10825526

Country of ref document: EP

Kind code of ref document: A2